SOTIO presented results from SOV02, the biotechnology company’s Phase II clinical trial evaluating DCVAC/OvCa – an active cellular immunotherapy product – in patients with recurrent ovarian cancer at 2019 SGO’s 50th Annual Meeting on Women’s Cancer.
Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U.S. FDA for Breakthrough Treatment of Depression
Aptar Pharma, a leading drug delivery systems provider, announced that the company’s Bidose nasal spray device was approved by the U.S. FDA for a breakthrough therapy in the field of depression.
New Study: Over-the-Counter (OTC) Products Used by Millions of Americans Saves Healthcare System Billions Annually
The Consumer Healthcare Products Association (CHPA) released a study – “Value of OTC Medicines to the U.S. Healthcare System” – finding on average that each dollar spent on over-the-counter medicines saves the U.S. healthcare system approximately $7.20, totaling nearly $146 billion in annual savings.
Aerie Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Vedolizumab Achieves Superior Rates of Clinical Remission vs. Adalimumab in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis
Takeda Pharmaceutical Company Limited announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab (Entyvio) was superior to the anti-tumor necrosis factor-alpha biologic adalimumab (Humira) in achieving clinical remission in patients with moderately to severely active ulcerative colitis at week 52.
ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies in Adults Living with HIV-1 Infection
ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.
Paige.AI was granted Breakthrough Device designation by the U.S. Food and Drug Administration, the first such designation for AI in cancer diagnosis publicly announced by any company.
W2O – an innovative, analytics-driven, digital-first marketing and communications firm – reported a 23 percent increase in revenue to $177 million in 2018 from $144 million in 2017.
IQVIA’s FluSTAR Online Dynamic Platform Helps Consumers Track Local Rates of Flu, Allergy and Asthma
IQVIA – a leader in human data science – provides consumers with quick and easy access to seasonal suffering data, giving them unique insights into important health related information. Recent data show that flu season is hitting hard in several key markets.
Personal Genome Diagnostics Welcomes New Members to Board of Directors, Bringing Proven, Industry-Leading Experience in Precision Medicine and Healthcare Policy
Personal Genome Diagnostics Inc., a leader in cancer genomics, announced that the company added two new members to the Board of Directors: Dr. Kavita Patel and Garry Allen Nicholson.